To support the development of new therapies for children, Pharmetheus commonly applies graphical analysis and model predictions comparing adult and pediatric data. In a recently published article, Daniel Röshammar and collaborators showed a similar relationship between dabigatran exposure and the effects on coagulation laboratory parameters in adults and children. The work supported age- and weight-adjusted dosing of dabigatran as appropriate in children with venous thromboembolism.
Find the publication here.
Pharmetheus affiliates: Daniel Röshammar
List of Daniel’s publications
Pharmetheus’ publications
